Background Lung cancer combined by chronic obstructive pulmonary disease (LC-COPD) is
a common comorbidity and their interaction with each other poses significant clinical …

Objective: Domestic PD-1inhibitor tislelizumab has emerged as a promising treatment for
Chinese patients with driver-negative advanced or metastatic non-small cell lung cancer …

目的探讨安罗替尼和氯喹(CQ) 单用及联用对人非小细胞肺癌系H1299 存活率, 迁移,
侵袭和凋亡的影响. 方法安罗替尼与CQ 单用及两药联合处理H1299 细胞, MTT …

Despite the benefit with cancer immunotherapies in clinical implication, immunotherapeutic
resistance occurred in many patients and the mechanism remains unknown. Increasing …

Tertiary lymphoid structures (TLSs) develop in non-lymphatic tissue in chronic inflammation
and cancer. TLS can mature to lymph node (LN) like structures with germinal centers and …

Objective Researches about the association between serum albumin-to-globulin ratio (AGR)
and the prognosis of lung cancer are limited. We aimed to investigate the relationship …

Lung cancer, as a malignant tumor with both high incidence and mortality in China, is one of
the major causes of death in our population and one of the major public health problems in …

Background Anlotinib, an oral small molecule tyrosine kinase inhibitor targeting VEGFR
1/2/3, FGFR 1-4, PDGFR a/β, and c-kit, had demonstrated prolonged progression-free …

Anlotinib is a novel multi-targeted tyrosine kinase inhibitor with activity against soft tissue
sarcoma, small cell lung cancer, and non-small cell lung cancer (NSCLC). Potentiating the …

Background Both protracted irinotecan and antiangiogenesis therapy have shown promising
efficacy against Ewing sarcoma (EWS). Methods Patients diagnosed with recurrent or …